Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI). All patients must have restarted the same TKI they were on prior to discontinuation at the time of relapse in order to be eligible for this trial.

NCT Number	NCT04838041
Lead Sponsor	Medical College of Wisconsin Collaborators: H. Jean Khoury Cure CML Consortium
Conditions	Chronic Phase Chronic Myelogenous Leukemia
Enrollment	51 participants
Start Date	2021-11-11
Primary Completion	2028-06 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2025-07-30